Helicobacter pylori infection
Conditions
Interventions
Dual therapy group:Vonoprazan 20 mg Bid, orally half an hour before breakfast and dinner
Amoxicillin 1 g Tid, orally half an hour after breakfast, lunch and dinner. 10 days.
Triple Therapy Group:Vonoprazan 20 mg Bid, orally half an hour before breakfast and dinner
Amoxicillin 1 g Bid, orally half an hour after breakfast and dinner
Clarithromycin 500 mg Bid, orally half an hour after breakfast and dinner. 14 days.
Quadruple therapy group:Vonoprazan 20 mg Bid, orally half an hour before breakfast and dinner
Bismuth Citrate Potassium 240 mg Bid, orally half an hour before breakfast and dinner
Amoxicillin 1 g Bid, orally half an hour before breakfast and dinner
Clarithromycin 500 mg Bid, orally half an hour after breakfast and dinner. 10 days.
Sponsors
The First Affiliated Hospital of Xiamen University
Eligibility
Sex/Gender
All
Age
18 Years to 69 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-69 years; 2. H. pylori infection was diagnosed by postive results in any one of the following tests: 13C or 14C-urea breath test, immunohistochemical staining, H. pylori culture, or fecal H. pylori antigen test; 3. No previous history of H. pylori eradication therapy; 4. Willingness to participate in the study and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Those who are allergic to any of the drugs used in this study; 2. Patients who had history of gastric surgery; 3. Patients with insufficiency in vital organs, such as the lungs, heart, liver and kidneys; 4. Patients who had history of taking antibiotics, bismuth, traditional Chinese medicine with antibacterial effect within four weeks, or proton-pump inhibitor, H2 receptor antagonists, non-steroidal anti-inflammatory drug within two weeks before inclusion; 5. Pregnant or lactating women; 6. Patients with psychiatric symptoms, drug addiction, severe neurocognitive disorders and other poor compliance or unable to cooperate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| H. pylori eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Compliance;Adverse events; | — |
Countries
China
Contacts
Public ContactZhang Jinyan
The First Affiliated Hospital of Xiamen University
Outcome results
None listed